Introduction
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors have recently been approved for the treatment of hypercholesterolaemia. 1 ,2 PCSK9 inhibitors dramatically lower LDL cholesterol levels by up to 62% compared with placebo within 6-12 weeks. [3] [4] [5] Lower LDL cholesterol levels are associated with a lower incidence of cardiovascular events, 6 including ischaemic stroke, 6, 7 which is the crux of the 'cholesterol hypothesis'. However, only one recently conducted randomized controlled trial (RCT) has shown lower incidence of ischaemic stroke in patients treated with PCSK9 inhibitors. 8 Furthermore, one RCT has reported a higher incidence of neurocognitive deficits in patients receiving PCSK9 inhibitors when compared with standard therapy, 9 whereas other RCTs did not show any increase in neurocognitive deficits in patients receiving these agents. 5, 8, [10] [11] [12] [13] [14] [15] [16] [17] Prior meta-analyses have contributed to the notion that PCSK9 inhibitors are 'neurologically unsafe' due to the increase in the incidence of neurocognitive adverse events with use of these inhibitors when compared with the controls. 18, 19 Given the variability in the reported rates of neurological outcomes of PCSK9 inhibitors, we conducted this investigation to assess the effect of these agents on ischaemic stroke and neurocognitive deficits. Due to lack of comparative data between the effects of alirocumab and evolocumab on neurocognition, we conducted post hoc subgroup meta-regression analyses to explore the association of class of antibody with the observed treatment effect on neurocognitive deficits.
Methods

Study inclusion and exclusion criteria
All RCTs published between January 1966 and March 2017 reporting any neurological effects in patients receiving the US Food and Drug Administration (US-FDA)-approved PCSK9 inhibitors were eligible for inclusion. 1, 2 The research study was conducted and reported in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) extension statement for meta-analyses (see Supplementary material online, Table S1 ). 20 The primary outcome of interest for our study was ischaemic stroke during follow-up. The secondary outcomes of interest were neurocognitive deficits. The definitions of these outcomes in the RCTs included in our analyses are presented in Supplementary material online, Tables S2 and S3.
Search strategy and quality assessment
Two authors (A.V. and N.P.) conducted an electronic literature search in SCOPUS. SCOPUS includes Medline, Embase, Compendex, World Textile Index, Fluidex, Geobase, and Biobase. 21 The keywords and search strategy are listed in see Supplementary material online, Section S1. One author (N.S.B.) verified the search results. We included all English language human studies. The abstracts were reviewed, and potential studies were identified. Full-text publications of these relevant studies were retrieved for detailed review. In the event of multiple publications from the same population and/or author, the study with the most complete data set was included. We reviewed the reference lists of relevant studies, in addition to clinicaltrials.org to identify other eligible studies. The Phase II and Phase III trials that contributed to larger Phase III trials (OSLER programme) were excluded. The trials reporting neither ischaemic stroke nor neurocognitive deficits were excluded. One author (N.P.) assessed the data quality of the included studies using the Jadad Score. Another author (R.K.) then independently assessed study scoring. The Jadad score is a tool that can be used to determine the quality of a study through examination of the methods of randomization, double blinding, and the number of dropouts. 22 A higher score indicates a higher quality study. 22 All inconsistencies were resolved by consensus among authors in weekly meetings.
Statistical analysis
Statistical analyses were performed using Stata 14.1 MP (Stata Corp., College Station, TX, USA) and CMA. A random-effects model was used to estimate the summary measures of treatment effects. Results were presented as risk ratios (RRs) with 95% confidence intervals (CIs). The I 2 statistic for heterogeneity, as proposed by Higgins and Thompson, was used to estimate heterogeneity among treatment effects in traditional meta-analyses. 23 Publication bias was assessed using Egger's regression intercept for the primary outcome comparison. 24 Subgroup analyses were conducted by the PCSK9 inhibitors type, i.e. evolocumab or alirocumab compared with no PCSK9 inhibitors. Exploratory meta-regression analysis using mixed-effects regression model (unrestricted maximum likelihood model) was used to assess the effect of duration of trial, baseline LDL levels, and change in LDL levels in PCSK9 inhibitors on the treatment effect.
Results
Randomized controlled trials stratified by phases (Phases I, II, and III) and antibody class (evolocumab, alirocumab, and bococizumab) published till date are represented in Figure 1 . Of these publications, we found 16 RCTs 8-17,25-27 with 39 104 patients eligible for the analyses ( Figure 2 and Table 1 ). All RCTs included in our final analyses were Phase III trials. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [25] [26] [27] Baseline characteristics of included studies and patients are presented in Table 1 . The mean/median age of patients of RCTs included in our analysis ranged from 31 years to 63 years. We compared two groups: the PCSK9 inhibitors group (both evolocumab and alirocumab) with the no PCSK9 inhibitors group (any of the four treatment strategies: placebo, placebo and ezetimibe, ezetimibe, and standard therapy), the details of which are listed in Table 1 . All included studies were categorized as good to excellent, based on the Jadad scale (see Supplementary material online, Table S4 ).
Comparison of neurological outcomes among those treated with PCSK9 inhibitors vs. no PCSK9 inhibitors
The incidence of ischaemic stroke was reported in 11 RCTs with 37 613 patients. 5, [8] [9] [10] [12] [13] [14] [15] 26 We observed a significantly lower risk of ischaemic stroke among those treated with PCSK9 inhibitors when compared with those without (RR 0.77, 95% CI 0.64-0.93; Figure 3A ). This effect was mainly driven by the recently reported FOURIER Trial. 8 The incidence of neurocognitive deficits was reported in 16 RCTs with 39 065 patients. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [25] [26] [27] We did not observe any difference in the incidence of neurocognitive deficits when we compared the PCSK9 inhibitors and the no PCSK9 inhibitors groups (RR 1.11, 95% CI 0.93-1.32; Figure 4A ).
Subgroup comparison of evolocumab and alirocumab vs. no PCSK9 inhibitors
Evolocumab was used in six RCTs with a total of 33 450 enrolled patients, 8, 9, 15, 26, 27 whereas alirocumab was used in 10 RCTs with a total of 5654 enrolled patients. 5, [10] [11] [12] [13] [14] 16, 17, 25 We observed that evolucumab had lower risk of stroke when compared with no PCSK9 inhibitors (RR 0.75, 95% CI 0.62-0.91), and we did not observe any difference in the risk of ischaemic stroke between the alirocumab and no PCSK9 inhibitors (RR 1.71, 95% CI 0.64-5.36) ( Figure 3B 
Publication bias assessment
We constructed a funnel plot of RCTs reporting ischaemic stroke and neurocognitive deficits ( Figure 5A and B) to assess for any publication bias for either outcome. The studies were distributed symmetrically around the estimated pooled effect, with Egger's weighted regression statistic (one sided, P = 0.2 for ischaemic stroke and P = 0.4 for neurocognitive deficits), indicating no significant publication bias for either outcome.
Meta-regression
In a meta-regression analyses, we found that the duration of RCT ( Figure 6A and B), baseline LDL ( Figure 7A and B), and change in LDL ( Figure 8A and B) did not have a statistically significant association with the observed effects on ischaemic stroke and neurocognitive deficits, with P > 0.05 for all.
Discussion
Our analyses highlight the neurological efficacy and safety of the US-FDA-approved PCSK9 inhibitors. 1, 2 We observed that the rates of ischaemic stroke were lower in patients treated with PCSK9 inhibitors. However, the rates of neurocognitive deficits were similar and not increased in patients treated with PCSK9 inhibitors. We also observed no effect of duration of trial, baseline LDL levels, and change in LDL levels with PCSK9 inhibitors on the neurological outcomes. Despite previous reports from epidemiological associations that lower LDL cholesterol levels led to a worse neurocognitive status, 28 our findings demonstrate no increase in neurocognitive deficits with the use of PCSK9 inhibitors. To the best of our knowledge, our analysis is the first and the largest to systematically examine the literature for the use of PCSK9 inhibitors and present comparisons Figure 1 Randomized controlled trials on PCSK9 inhibitors. Black diamond represents studies lacking desired outcomes; blue diamond represents studies using non-US-FDA-approved PCSK9 inhibitors; green diamond represents studies with overlapping population with OSLER 1 study; and maroon diamond represents studies with overlapping population with OSLER 2 study. between the two PCSK9 inhibitors, with a primary focus on neurological outcomes. There may be several mechanistic explanations for the ischaemic stroke reduction witnessed in our investigation. As LDL has been known to play a causal role in atherosclerotic events, it follows that aggressive reduction of LDL levels reduces incidence of cardiovascular events. 29 This seems to be the most direct explanation and wellaccepted reasoning for the reduction of ischaemic stroke as well. This LDL reduction effect is undoubtedly magnified by the PSKC9 inhibition to counter the PCSK9 gene up-regulation that statins are known to cause. 30 Treatment with PCSK9 inhibitors also seems to offer additional notable improvements in other components of the lipid profile. This includes improvement in HDL and reductions in apolipoprotein B and lipoprotein A to unprecedented levels. Given the emerging data linking lipoprotein A to the increased development of atherosclerotic disease, 31, 32 reductions in these other lipids may be an important additional mechanism through which PCSK9 inhibitors reduce the incidence of atherosclerotic disease. We also acknowledge that the stroke reduction was largely driven by the results of the FOURIER trial. Forest plot comparing the incidence of neurocognitive deficits between PCSK9 inhibitor and the no PCSK9 inhibitor groups in subgroups. The blue diamond is the point estimate representing the 95% confidence interval. The red dotted lines represent the random effects generated overall estimate. Data are presented with risk ratios and 95% confidence intervals. RR: risk ratio, PCSK9: proprotein convertase subtilisin/kexin type 9. The absence of differences in neurocognitive deficits in our metaanalyses can be explained by the following observations. Only two studies in our meta-analysis, OSLER 1 and 2 and ODYSSEY LONG TERM, 9,14 noted three-fold and two-fold higher risk of neurocognitive deficits, respectively, among those treated with PCSK9 inhibitors. All other studies either showed reduction or neutral effects of PCSK9 inhibitors on neurocognitive deficits. 8, [10] [11] [12] [13] [14] [15] [16] [17] One potential explanation is the lack of standardized cognitive testing and reliance on patient's self-reporting of what constituted as a neurocognitive deficit. This may have led to a reporting bias contributing to the increase in neurocognitive deficits noted in the earlier studies especially in the OSLER studies which were an open-label trial. 9 In comparison, the FOURIER trial did not notice any increase in neurocognitive events. 8 Concordant to our pooled results were the null observations from the EBBINGHAUS 33 (NCT02207634), a substudy of the FOURIER trial that had formal assessment of neurocognition using a cognitive assessment tool followed by an independent adjudication of all neurocognitive outcomes. 8 The results of our meta-analysis are also consistent with the genetic studies of patients with loss of function of PCSK9, with no increase in the incidence of cognitive events. 34, 35 Having said that, we would like to acknowledge the observation that the antibodies produced against alirocumab as noticed in ODYSSEY LONG TERM trial (which noted two-fold higher neurological deficits) are thought to play a 'functional' role in causing the adverse neurological outcomes with alirocumab usage. 14 If there is a physiological explanation, we posit that this may be a legitimate theory. This is particularly relevant in view of the recent discontinuation of bococizumab drug development due to the same issue. 36 Other mechanisms have also been hypothesized such as detection bias rather than a causal association. 37 This area clearly needs to be examined further before additional causal explanations can be offered. Our investigation offers an interesting contrast to the prior investigations pertaining to stroke reduction with PCSK9 inhibitors. Milionis et al. 38 have published a meta-analysis article evaluating the rates of ischaemic stroke, by pooling two studies, ODYSSEY LONG TERM and OSLER. 9, 14 Their investigation concludes that the incidence of ischaemic strokes was similar in patients who were treated with PCSK9 inhibitors and patients who were not treated with PCSK9 inhibitors. 38 This investigation is limited by the lack of a systematic search strategy. 38 Consequently, there are several missing studies, and the Milionis et al. 38 investigation does not capture the totality of the published literature, making their investigation prone to significant publication bias. Khan et al. 18 also published a meta-analysis evaluating the rates of ischaemic stroke with the use of PCSK9 inhibitors. The authors have divided the studies into two groups, early Phase II-III studies and long-term studies, and concluded that the incidence of ischaemic strokes were similar. 18 Both of these investigations also lack the cohorts included in the FOURIER/EBBINGHAUS and GLAGOV trials. 8, 15 Our findings also add to the existing literature on neurocognitive deficits associated with PCSK9 inhibitors. Lipinski et al., 19 Robinson et al., 39 and Khan et al. 18 published the meta-analyses that estimated the rates of neurocognitive deficits with the use of PCSK9 inhibitors, The point estimate of their pooled results 19 were primarily driven by the ODYSSEY LONG TERM and OSLER studies. 9, 14 However, with the data available from the additional RCTs that we included in our meta-analyses, 8, [10] [11] [12] [13] [15] [16] [17] [25] [26] [27] we found that there is no increase in the pooled rates of neurocognitive deficits with the use of PCSK9 inhibitors. Khan et al. 18 divided the available studies into two groups, early Phase II and Phase III studies and outcome studies, and concluded that there is an increase in neurocognitive deficits with larger sample size and longer follow-up. However, their findings were also primarily driven by the ODYSSEY LONG TERM and OSLER studies. 9, 14 In a recent article, patient-level pooled data were reported from 14 RCTs included in the ODYSSEY programme. 39 Concordant to our findings, the authors reported no differences in the rates of neurocognitive effects between the alirocumab and the control groups. Furthermore, no increase in neurocognitive disorders were reported even at LDL levels <25 mg/dL. 39 Having said that, none of the previously published meta-analyses used the two US-FDAapproved antibodies alirocumab and evolocumab in subgroups, to evaluate their neurological efficacy and safety, as we did. 18, 19, 38, 39 Once again, our investigation also includes the contemporary literature.
8,15
The results of our investigation also have notable implications for clinical practice, public health, and future research. The absence of increased neurocognitive deficits with the use of PCSK9 inhibitors may aid clinicians in making therapeutic decisions while treating patients who require PCSK9 inhibitors from a cardiovascular standpoint. Our investigation also highlights the importance of conducting larger studies to directly assess the comparative efficacy and safety of alirocumab and evolocumab. We anticipate that the results of the ODYSSEY OUTCOMES trial (ClinicalTrials.gov, NCT01663402), which aims to address the long-term effects of alirocumab on cardiovascular outcomes and ischaemic stroke risk in a cohort of 18 000 patients over the course of 5 years, will form a greater evidence base to evaluate the neurological efficacy and safety profiles of PCSK9 inhibitors. Finally, the health care costs associated with PCSK9 inhibitors are difficult to ignore, despite their remarkable efficacy. The PCSK9 inhibitors were evaluated through a thorough cost-benefit analysis and that needs to be weighed in prior to using them in clinical practice. 42 Our study has several limitations. Limitations of meta-analyses are, in general, well recognized. 43 We note that our findings were only valid in the relatively younger population included in these RCTs and need to be corroborated in elderly individuals prior to the widespread use of these drugs. Further limitations of our analysis include the pooling of different drugs, dosages, and duration of treatment. However, variability in efficacy and safety outcomes was not apparent among individual studies, despite different doses and durations, suggesting that these variations are less likely to affect the validity of our results. Although our meta-regression analyses did not demonstrate any effect of duration on neurological outcomes, the included patients and the study characteristics among the included RCTs were different. We attempted to temporize this by utilizing random-effects modelling rather than fixed-effects modelling to ensure conservative effect estimates. Finally, many of the studies included in these metaanalyses were not primarily designed to evaluate neurological outcomes. Hence, the results of our meta-analyses should be seen as hypothesis generating.
Conclusions
In summary, PCSK9 inhibitors are a novel class of drugs that result in substantial alterations in lipid profiles. In our meta-analyses, we found that they reduce the incidence of ischaemic stroke. We have not found any evidence of increased neurocognitive deficits with the use of PCSK9 inhibitors, as previously reported. Ongoing studies will help to elucidate the long-term neurological efficacy and safety outcomes of these drugs.
